Thu, May 15, 10:10 AM (37 days ago)
**PAVMED Inc. (PAVM) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0.1 million (Q1 2024: $1.0 million) - **Operating Expenses:** $5.5 million (Q1 2024: $15.0 million) - **Operating Loss:** $5.4 million (Q1 2024: $14.0 million) - **Net Income:** $18.7 million (Q1 2024: -$15.2 million) - **Cash Flow from Operations:** -$1.6 million (Q1 2024: -$13.1 million) **Profit Margins:** - **Gross Margin:** Not explicitly stated, but implied to be low due to high operating expenses. - **Operating Margin:** -98.2% (Q1 2024: -1400%) **Cash Flow:** - **Operating Cash Flow:** -$1.6 million (Q1 2024: -$13.1 million) - **Investing Cash Flow:** -$0.1 million (Q1 2024: -$0.1 million) - **Financing Cash Flow:** $3.1 million (Q1 2024: $19.0 million) **Earnings Changes:** - **EPS (Basic):** $1.28 (Q1 2024: -$2.62) - **EPS (Diluted):** $0.34 (Q1 2024: -$2.62) **Quarterly Performance:** - **Revenue Growth:** -99% YoY - **Operating Expense Reduction:** 63% YoY - **Net Income Improvement:** Significant improvement due to non-operating items **Trends & Uncertainties:** - **Revenue Trends:** Declining revenue from core operations. - **Expense Trends:** Significant reduction in operating expenses due to deconsolidation of Lucid. - **Future Operations:** Continued reliance on equity and debt financing. Uncertainty around regulatory approvals and market acceptance of products. **Future Outlook:** - **Revenue Growth:** Uncertain, dependent on successful commercialization of products. - **Expense Management:** Continued focus on cost control. - **Cash Flow:** Negative operating cash flow expected to continue, reliant on financing activities. **Going Concern:** - **Liquidity:** Negative working capital of $6.1 million. - **Cash Position:** $2.7 million in cash. - **Debt Obligations:** Significant debt obligations and financial covenants. **Ticker:** PAVM